

REMARKS

The sole basis for rejection in the outstanding Office action relates to alleged scope of enabling disclosure. The Office acknowledges, at page 3 of the action, enablement relating to determining presence or risk of breast cancer by evaluating a patient sample for increased expression of the gene at issue in the sample compared to normal control breast tissue.


Although the application is enabling for additional embodiments of the invention, to expedite allowance the Applicants have amended the claims to be commensurate in scope with the invention that the Office has acknowledged to be enabled. Accordingly, the rejection is moot, and should be withdrawn.

The amendment to claim 5 finds support throughout the application, including at page 8, lines 28-31.

In view of the foregoing the application is believed to be in condition for allowance.

Dated: June 14, 2010

Respectfully submitted,

By 
David A. Gass

Registration No.: 38,153
MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive
6300 Willis Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Attorney for Applicant